Insomnia refers to persistent difficulty initiating sleep, maintaining sleep, or achieving restorative sleep, despite adequate opportunity and circumstances for sleep. In the provided context, the phrase “Can’t sleep anymore” suggests sleep maintenance insomnia—waking frequently or early and struggling to return to sleep. Clinically, insomnia is not synonymous with simple tiredness; it is defined by the combination of sleep disruption and daytime impairment such as fatigue, impaired attention, mood disturbance, and reduced functioning. Insomnia can be transient, but when symptoms occur at least three nights per week for three months or more, it meets criteria for chronic insomnia.
Neurobiology helps explain why insomnia can become self-perpetuating. Sleep-wake regulation relies on a circadian timing system driven largely by the suprachiasmatic nucleus, and a homeostatic drive that increases with time spent awake. In insomnia, misalignment between circadian timing and the sleep pressure signal can reduce sleep propensity. In parallel, hyperarousal—heightened cognitive, physiological, and autonomic activation—amplifies wakefulness. This hyperarousal often involves increased cortical activation, altered stress-axis signaling, and changes in neurotransmitter balance, including reduced inhibitory tone from GABAergic pathways and dysregulated arousal signaling involving orexin/hypocretin. Orexin promotes wakefulness and can remain overactive in certain insomnia phenotypes, particularly those with frequent awakenings.
Cognitive processes also matter. Cognitive arousal and dysfunctional beliefs (e.g., “If I don’t sleep, tomorrow will be ruined”) can lead to sleep-related threat monitoring. Individuals may engage in compensatory behaviors—extended time in bed, checking the clock, or napping—that further fragment sleep. This creates a feedback loop: poor sleep increases anxiety about sleep, which increases arousal, which worsens sleep.
Differential diagnosis is essential because insomnia can be secondary to other conditions. Depression and anxiety disorders are common contributors; insomnia may precede or accompany them. Restless legs syndrome and periodic limb movement disorder cause uncomfortable sensations or repetitive leg movements that fragment sleep. Obstructive sleep apnea produces arousals from airway obstruction and is often underrecognized, especially in individuals who present primarily with insomnia rather than loud snoring. Medical conditions such as chronic pain, gastroesophageal reflux disease, hyperthyroidism, and medication effects (e.g., stimulants, some antidepressants, corticosteroids, decongestants, and excessive caffeine) can also impair sleep. Substance use (including alcohol-related sleep fragmentation) and withdrawal states are additional causes.
Assessment typically includes sleep diaries, questionnaires such as the Insomnia Severity Index, screening for comorbid sleep disorders, and review of medications and substances. Clinicians should assess sleep opportunity, circadian pattern, nocturnal symptoms (snoring, witnessed apneas, leg discomfort), and daytime impairment. Polysomnography is considered when obstructive sleep apnea, periodic limb movement disorder, or other complex sleep disorders are suspected; it is not routinely required for uncomplicated chronic insomnia.
Treatment is most effective when it targets both arousal and maladaptive behaviors. The first-line therapy for chronic insomnia is cognitive behavioral therapy for insomnia (CBT-I), which integrates stimulus control, sleep restriction therapy (to consolidate sleep and increase drive), cognitive restructuring, sleep hygiene (as an adjunct, not a standalone cure), and relaxation strategies. Stimulus control reduces conditioning between bed and wakefulness by strengthening the association of bed with sleep. Sleep restriction temporarily limits time in bed to the average actual sleep time, increasing sleep pressure and efficiency; once consolidated, time in bed is gradually increased.
Pharmacotherapy may be used short term or when CBT-I access is limited, but it requires careful selection due to tolerability and risks. Common classes include non-benzodiazepine hypnotics and benzodiazepine receptor agonists for sleep initiation or maintenance, orexin receptor antagonists for certain insomnia phenotypes, and melatonin receptor agonists in selected cases. Antidepressants with sedating properties may be considered when comorbid depression or anxiety exists, though they are not universally appropriate. Risks include next-day impairment, falls (especially in older adults), dependence or tolerance (for some agents), and potential worsening of sleep-related breathing disorders in untreated apnea.
Lifestyle and behavioral optimization matter: maintaining consistent wake times, limiting caffeine after mid-day, avoiding alcohol as a sleep aid, and engaging in regular daytime physical activity can reduce arousal. Relaxation techniques such as mindfulness, paced breathing, or progressive muscle relaxation can lower physiological activation. For sleep maintenance insomnia, reducing time awake in bed and preventing clock monitoring are particularly helpful.
Finally, if insomnia persists, evaluation for comorbid mental health conditions and medical contributors should be prioritized. When insomnia is addressed comprehensively—by treating underlying disorders, correcting circadian and behavioral drivers, and using evidence-based CBT-I strategies—sleep quality often improves with sustained benefits. Source: @JohnnyForeRight
John Moran: Can’t sleep anymore. Might as well get up, make dippy egg and toast and log into work. Nothing disappoints like a broken yolk. Make it a good Wednesday, even if your yolk is broken #ButFirstCoffee. #breaking
— @JohnnyForeRight May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
